A Pilot Study to Assess the Acceptability, Tolerability, and Feasibility of Home Intranasal Administration of FluMist® by a Trained Primary Caregiver to Healthy Family Members 2 Through 17 Years of Age
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 41
- Locations
- 1
- Primary Endpoint
- Number of Subjects That Reported Successful Home Vaccination With no Adverse Events
Study Overview
Brief Summary
This study will examine the feasibility of having parents and caregivers administer FluMist live intranasal vaccine to their children at home outside the traditional medical environment and without the involvement of medical personnel.
The study will recruit patients and families that are already eligible to receive the FluMist vaccine. After consent is obtained and vaccine is given to the family, they will go home to administer vaccine to other members within 24 hours. Telephone follow up within 48 hours will confirm that vaccine was given successfully and within 9-12 days to assess patient preferences for giving vaccine at home and if there were any adverse events.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 2 Years to 17 Years (Child)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •The primary caregiver must be 18 years of age or older and willing to give written informed consent for study participation
- •The primary caregiver must be the parent or legal guardian of all the children in living in the household
- •All the children in the household who are 2 through 17 years of age must receive their primary care in the clinic
- •All the children in the household who are 2 through 17 years of age must have private insurance that will provide for the cost of influenza vaccination
- •There must be at least one member of the household who is 2 through 17 years of age, presenting for care in the clinic, eligible to receive Live Attenuated Influenza Vaccine (LAIV) and whose primary care giver is willing to administer LAIV to them in the clinic with supervision
- •There must be at least one family member of the household who is 2 through 17 years of age, not presenting for care in the clinic, eligible to receive LAIV and whose primary care giver is willing to administer LAIV to them in the in-home setting
- •There must be a working refrigerator in the household
- •The primary caregiver must have a working telephone number and be willing to be contacted for study follow-up by telephone or e-mail
- •The primary caregiver is available for the entire study period - 12 days following the last dose of LAIV to be administered to a child
- •The primary caregiver must agree to complete a 30 minute post vaccination assessment and an 8 day diary following vaccination for each child receiving LAIV.
Exclusion Criteria
- •Children in the family receive vaccine through Vaccines for Children program
Arms & Interventions
FluMist
Subjects receiving vaccine at home
Intervention: FluMist (Biological)
Outcomes
Primary Outcomes
Number of Subjects That Reported Successful Home Vaccination With no Adverse Events
Time Frame: 0-12 days
We will assess the tolerability of giving the FluMist nasal vaccine at home by parents/caregivers to their children by performing telephone survey follow up. We will ask parents at both 24-48 hours and at 9-12 days after study visit and enrollment about any difficulties in giving FluMist at home and any adverse events encountered when giving FluMist at home.
Secondary Outcomes
- Number of Subjects That Reported Ability to Successfully Administer FluMist Vaccine at Home(0-12 days)